Telo Genomics Corp. develops diagnostic and prognostic tests for human disease using 3D analysis of chromosomal telomeres. News about TDSGF centers on the company’s telomere analytics platform, including TeloView® and blood-based minimal residual disease testing for multiple myeloma.
Recurring updates include retrospective clinical studies and academic collaborations, presentations at hematology and myeloma meetings, laboratory-capacity developments, and corporate governance changes. Company announcements also describe work with circulating tumor cells, individual-cell risk profiling, and the use of liquid-biopsy workflows to assess relapse risk in oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.